Press Release – September 1st 2016

Signature of a license agreement between 4P-Pharma, SATT-Aquitaine and University of Bordeaux for the development of an anti-cancer drug.

 

Talence, September 1st

4P-Pharma has signed an exclusive license agreement with Aquitaine Science Transfert, for the development of a drug targeting pancreatic cancer, triple negative breast cancer or colon cancer. The molecule was first developed and patented by researchers from the laboratory of Angiogenesis and Cancer Microenvironment (LAMC – University of Bordeaux / Inserm).This signature materializes the technology transfer process managed by Inserm Transfert and the SATT Aquitaine. The funding for the project maturation amounts to 375 k€ over a 3-year time frame.

 

satt aquitaine logo4p-pharma

 

 

 

 

Read the full press release :
EN: Press Release 4P-Pharma SATT Aquitaine License agreement

FR: Communiqué de presse 4P Pharma-SATT Aquitaine 2016

 

Watch the video of the event

 

Press contact Aquitaine Science Transfert

Claire Moras, communications manager

E-Mail : c.moras@ast-innovations.com. Phone : 33 (0)5 33 51 43 28 . Cell: 06 19 57 48 66 .

Yann Mondon, marketing and communications director.

E-Mail : y.mondon@ast-innovations.com. Phone : +33 (0)6 30 51 22 94 . Cell : 06 30 51 22 94 .

 

Press contact 4P-Pharma

Keren Bismuth, scientific communications manager.

E-mail: keren@4p-pharma.com. Phone :33 (0)9 72 84 72 64.